Literature DB >> 32243672

SARS Cov-2 infection in a renal-transplanted patient: A case report.

Elena Seminari1, Marta Colaneri1, Margherita Sambo1, Ilaria Gallazzi1, Angela Di Matteo1, Silvia Roda1, Raffaele Bruno1.   

Abstract

The clinical manifestation of COVID-19 can vary from an asymptomatic course to ARDS requiring invasive mechanical ventilation and extracorporeal membrane oxygenation. A kidney transplanted patient infected with SARS CoV-2 infection showed a mild disease despite immune suppression. It is possible that Immunosuppression can "be protective" as the cytokine storm is an important factor in the disease story. Despite the good outcome reported in the present case report, is remains of vital importance the solid organ transplant patients use precautions in order to avoid the infection.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; immunosuppressant - calcineurin inhibitor: tacrolimus; infection and infectious agents - viral; infectious disease

Mesh:

Substances:

Year:  2020        PMID: 32243672     DOI: 10.1111/ajt.15902

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  47 in total

1.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

Review 2.  Transplantation in Asia during the coronavirus disease-19 (COVID-19) pandemic: briefs from member countries of the Asian Society of Transplantation.

Authors:  Terence Kee; Jong Cheol Jeong; Jongwon Ha; Harun Ur Rashid; Nura Afza Salma Begum; Maggie K M Ma; Vivek Kute; Kenji Yuzawa; Rosnawati Yahya; Ghazali Ahmad; Lkhaakhuu Od-Erdene; Dibya Singh Shah; Romina A Danguilan; Curie Ahn; Devinder Singh Rana
Journal:  Korean J Transplant       Date:  2020-06-30

Review 3.  COVID-19 Mortality in Transplant Recipients.

Authors:  M Alfishawy; A Elbendary; M Mohamed; M Nassar
Journal:  Int J Organ Transplant Med       Date:  2020

4.  The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature.

Authors:  Roberta Angelico; Francesca Blasi; Tommaso Maria Manzia; Luca Toti; Giuseppe Tisone; Roberto Cacciola
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

Review 5.  Solid Organ Transplantation During the COVID-19 Pandemic.

Authors:  Hedong Zhang; Helong Dai; Xubiao Xie
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

Review 6.  Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.

Authors:  Catharina Korsukewitz; Stephen W Reddel; Amit Bar-Or; Heinz Wiendl
Journal:  Nat Rev Neurol       Date:  2020-07-08       Impact factor: 44.711

7.  Expedited SARS-CoV-2 screening of donors and recipients supports continued solid organ transplantation.

Authors:  Joshua A Lieberman; James A Mays; Candy Wells; Anne Cent; Deborah Bell; Daniel D Bankson; Alexander L Greninger; Keith R Jerome; Ajit P Limaye
Journal:  Am J Transplant       Date:  2020-06-23       Impact factor: 9.369

Review 8.  From causes of aging to death from COVID-19.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2020-06-12       Impact factor: 5.682

Review 9.  SARS-CoV2 and immunosuppression: A double-edged sword.

Authors:  Quirino Lai; Gabriele Spoletini; Giuseppe Bianco; Dario Graceffa; Salvatore Agnes; Massimo Rossi; Jan Lerut
Journal:  Transpl Infect Dis       Date:  2020-07-17

10.  Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States.

Authors:  Olivia S Kates; Cynthia E Fisher; Helen C Stankiewicz-Karita; Amanda K Shepherd; E Chandler Church; Siddhartha G Kapnadak; Erika D Lease; Francis X Riedo; Robert M Rakita; Ajit P Limaye
Journal:  Am J Transplant       Date:  2020-05-08       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.